Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP002 in Malignant Digestive System Neoplasms
NCT04755543Phase 1Unknown
- Sponsor
- Taizhou Houde Aoke Technology
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of LP002 in malignant digestive system neoplasm, Gastric carcinoma (GC), gastroesophageal junction carcinoma (GEJ) and 1 more (5 arms), sponsored by Taizhou Houde Aoke Technology. Primary endpoint: Treatment-related adverse events at 24 months. Status: unknown.
02
Drugs
LP002
03
Conditions
malignant digestive system neoplasmGastric carcinoma (GC)gastroesophageal junction carcinoma (GEJ)esophageal carcinoma
Beyond the preview
Go deeper on NCT04755543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755543.